Syntrix Biosystems, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Auburn WA United States (1999)

Organization Overview

First Clinical Trial
2009
NCT00937027
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Syntrix Biosystems | Syntrix Biosystems, Inc. | Syntrix Pharmaceuticals

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Chronic Pain (Phase 2)

Colorectal Neoplasms (Phase 2)

Diabetic Neuropathies (Phase 2)

Disease Progression (Phase 1)

Melanoma (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Neuralgia (Phase 2)

Pancreatic Neoplasms (Phase 1)

Preleukemia (Phase 1)

Psoriasis (Phase 2)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 13
  • # of Trial APIs: 8